<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492528</url>
  </required_header>
  <id_info>
    <org_study_id>2017-50</org_study_id>
    <secondary_id>2017-A03362-51</secondary_id>
    <nct_id>NCT03492528</nct_id>
  </id_info>
  <brief_title>Cardiovascular Outcome of Cancer Patients: The &quot;GMEDICO Cohort&quot;</brief_title>
  <acronym>GMEDICO</acronym>
  <official_title>Cardiovascular Outcome of Cancer Patients: The &quot;GMEDICO Cohort&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Mediterranean Group of Cardio-Oncology (GMEDICO) brings together French cardiologists and&#xD;
      oncologists who have developed a protocol for the monitoring and cardio-oncological&#xD;
      management of patients treated for cancer.&#xD;
&#xD;
      This unique organization makes it possible to envisage the creation of a large cohort from&#xD;
      which the incidence and predictive factors of cardiovascular toxicity can be determined.&#xD;
&#xD;
      Primary objective: to determine the cardiovascular prognosis of patients treated for cancer&#xD;
      and followed up in cardio-oncology.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  To determine the clinical, biological and imaging factors associated with cardiovascular&#xD;
           events under cancer treatment, in order to define a risk score including clinical,&#xD;
           biological (biomarker) and imaging data.&#xD;
&#xD;
        -  To create a biological source for testing other biomarkers and conducting genome-wide&#xD;
           association studies and genetic factors associated with cardiovascular events under&#xD;
           cancer treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will be monitored for 5 years. Cardio-oncological follow-up and management&#xD;
      within these centers will follow a common protocol established and validated in March 2016 on&#xD;
      the basis of international recommendations and summaries of the characteristics produced for&#xD;
      each drug. Additional blood samples will be taken for the biobanking. Depending on the case,&#xD;
      a small skin biopsy will be carried out to analyze the cardiovascular response of in vitro&#xD;
      immunotherapy using a reprogramming model of fibroblasts in hiPSC hiPSC (human induced&#xD;
      Pluripotent Stem cells)-cardiomyocytes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage of cardiac biomarkers</measure>
    <time_frame>5 YEARS</time_frame>
    <description>dosage of troponine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">530</enrollment>
  <condition>Cardiovascular Prognosis</condition>
  <arm_group>
    <arm_group_label>Cardiovascular patients treated for a cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>blood samples</description>
    <arm_group_label>Cardiovascular patients treated for a cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adults referred for specialist cardio-oncology consultations before the initiation&#xD;
             of a cancer treatment according to pre-established indications will be eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to provide information that makes it impossible to complete a consultation&#xD;
             form or refuse to sign the consent.&#xD;
&#xD;
          -  Minor or major patient under guardianship&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique-HÃ´pitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>franck thuny</last_name>
    <phone>33(0)4 91 96 86 83</phone>
    <email>franck.thuny@ap-hm.fr</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

